Clinical implications of extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteraemia

Journal of Hospital Infection

Volumn 52, Issue 2, 2002, Pages 99-106

  Kim, B N ^a   Woo, J H ^a   Kim, M N ^a   Ryu, J ^a   Kim, Yang Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

lactamase; Bacteraemia; Klebsiella pneumoniae; Resistance

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BILIARY TRACT DRAINAGE; BILIARY TRACT INFECTION; BLOOD CULTURE; CATHETER; FEMALE; GRAM NEGATIVE SEPSIS; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; ADOLESCENT; CROSS INFECTION; DRUG EFFECT; ENTEROBACTER INFECTION; ENZYMOLOGY; ISOLATION AND PURIFICATION; KOREA; METABOLISM; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; PATHOGENICITY; PROGNOSIS; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BETA-LACTAMASES; CROSS INFECTION; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; KOREA; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

EID: 0036780839     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhin.2002.1288     Document Type: Article

References (31)

1. Paterson, DL, & Yu, VL (1999). Extended-spectrum beta- lactamases: a call for improved detection and control. Clin Infect Dis, 29 1419-1422.
2. Jacoby, GA (1997). Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino- beta-lactams. Infect Dis Clin North Am, 11 875-887.
3. Wiener, J, Quinn, JP, & Bradford, PA et al. (1999). Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. J Am Med Assoc, 281 517-523.
4. D'Agata, E, Venkataraman, L, DeGirolami, P, Weigel, L, Samore, M, & Tenover, F (1998). The molecular and clinical epidemiology of Enterobacteriaceae-producing extended-spectrum beta-lactamase in a tertiary care hospital. J Infect, 36 279-285.
5. Meyer, KS, Urban, C, Eagan, JA, Berger, BJ, & Rahal, JJ (1993). Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med, 119 353-358.
6. Paterson, DL (2000). Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect, 6 460-463.
7. Patterson, JE (2000). Extended-spectrum beta-lactamases. Semin Respir Infect, 15 299-307.
8. Schiappa, DA, Hayden, MK, & Matushek, MG et al. (1996). Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis, 174 529-536.
9. Lucet, JC, Chevret, S, & Decre, D et al. (1996). Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis, 22 430-436.
10. Pena, C, Pujol, M, & Ardanuy, C et al. (1998). Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta- lactamases. Antimicrob Agents Chemother, 42 53-58.
11. Rice, LB, Eckstein, EC, DeVente, J, & Shlaes, DM (1996). Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis, 23 118-124.
12. Lautenbach, E, Patel, JB, Bilker, WB, Edelstein, PH, & Fishman, NO (2001). Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis, 32 1162-1171.
13. Menashe, G, Borer, A, & Yagupsky, P et al. (2001). Clinical significance and impact on mortality of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis, 33 188-193.
14. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, ninth informational supplement. Wayne, PA: National Committee for Clinical Laboratory Standards 2000; M100-S10.
15. Jarlier, V, Nicolas, MH, Fournier, G, & Philippon, A (1988). Extended spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis, 10 867-878.
16. McCabe, WR, & Jackson, GG (1962). Gram-negative bacteremia. II. Clinical, laboratory, and therapeutic observations. Arch Intern Med, 110 856-864.
17. Horan, TC, Gaynes, RP, Martone, WJ, Jarvis, WR, & Emori, TG (1992). CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Am J Infect Control, 20 271-274.
18. Medeiros, AA (1997). Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis, 24 S19-S45.
19. Rahal, JJ, Urban, C, & Horn, D et al. (1998). Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA, 280 1233-1237.
20. Lucet, JC, Decre, D, & Fichelle, A et al. (1999). Control of a prolonged outbreak of extended-spectrum beta- lactamase-producing Enterobacteriaceae in a university hospital,. Clin Infect Dis, 29 1411-1418.
21. Chong, Y, & Lee, K (2000). Present situation of antimicrobial resistance in Korea. J Infect Chemother, 6 189-195.
22. Pai, H, Lyu, S, & Lee, JH et al. (1999). Survey of extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea. J Clin Microbiol, 37 1758-1763.
23. Kim, J, Kwon, Y, Pai, H, Kim, JW, & Cho, DT (1998). Survey of Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: prevalence of SHV-12 and SHV-2a in Korea. J Clin Microbiol, 36 1446-1449.
24. de Champs, C, Rouby, D, & Guelon, D et al. (1991). A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase. J Hosp Infect, 18 5-13.
25. Gould, IM (1994). Risk factors for acquisition of multiply drug-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis, 13 S30-S38.
26. Pena, C, Pujol, M, & Ardanuy, C et al. (2001). An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase. J Hosp Infect, 47 53-59.
27. Rebuck, JA, Olsen, KM, Fey, PD, Langnas, AN, & Rupp, ME (2000). Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis, 31 1368-1372.
28. Siu, LK, Lu, PL, & Hsueh, PR et al. (1999). Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes. J Clin Microbiol, 37 4020-4027.
29. Paterson, DL, Ko, WC, & Gottberg, AV et al. (2001). Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol, 39 2206-2212.
30. Livermore, DM, & Yuan, M (1996). Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother, 38 409-424.
31. Ahmad, M, Urban, C, & Mariano, N et al. (1999). Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis, 29 352-355.